Phase II trial of miniDOX (reduced dose docetaxel–oxaliplatin–capecitabine) in “suboptimal” patients with advanced gastric cancer (AGC). TTD 08-02

Rivera, Fernando; Massutí, Bartomeu; Salcedo, Matilde; Sastre, Javier; Martínez-Galán, Joaquina; Valladares‐Ayerbes, Manuel; Serrano, Raquel; Paredes, M L García de; Manzano, José Luís; Galan, MaCarmen; Alsina, María; Izquierdo, A.; López, Carlos; Dı́az-Rubio, Eduardo; Conde, V.; Reboredo, Margarita; Cano, M. Teresa; Pachón, V.; Aranda, Enrique

doi:10.1007/s00280-014-2641-3

Cited by 14 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite a similar toxicity profile seen in the over and under 70 groups between both treatments, a significant deterioration in quality of life was demonstrated in patients on FLOT. The phase II miniDOX trial of reduced dose triplet regime, docetaxel, oxaliplatin and capecitabine, in advanced gastric cancer patients considered 'suboptimal' (defined as age ≥70, performance status 2 or weight loss of 10-25%) showed a comparable response rate to the equivalent phase II GATE study in good prognostic groups (73), however the toxicity profile was significant (74).…”

Section: Palliative Chemotherapymentioning

confidence: 97%

Challenges in the treatment of gastric cancer in the older patient

Joharatnam‐Hogan

Shiu

Khan

2020

Cancer Treatment Reviews

View full text Add to dashboard Cite

Section: Palliative Chemotherapymentioning

confidence: 97%

Challenges in the treatment of gastric cancer in the older patient

Joharatnam‐Hogan

Shiu

Khan

2020

Cancer Treatment Reviews

View full text Add to dashboard Cite

“…-Most of other published studies exploring different chemotherapy regimens in older patients are small phase II studies or retrospective analyses (Table 4) [79][80][81][82][83][84][85][86][87][88][89][90][91][92][93][94][95][96][97]. Among them, the most interesting study is the randomized phase II 321GO trial, which led to the phase III GO2 trial [95].…”

Section: Hematologic Risk Factorsmentioning

confidence: 99%

“…No treatment-related death or symptomatic congestive heart failure were observed. Several phase II studies testing oxaliplatin instead of cisplatin in combination with trastuzumab (and 5FU or S1) have shown interesting efficacy and tolerance results leading to a large use in both routine practice and clinical trials [93,110].…”

Section: Chemotherapy In Older Patients With Metastatic Her2 Positive Gcmentioning

confidence: 99%

Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature

Fouchardiere

Decoster

Samalin

et al. 2021

Cancer Treatment Reviews

View full text Add to dashboard Cite

Gastric (G) and gastro-esophageal junction (GEJ) adenocarcinomas are of the most common and deadly cancers worldwide and affect mainly patients over 70 years at diagnosis. Older age has been associated in gastric cancers with distal tumour location, well-differentiated adenocarcinoma and microsatellite instability and is not identified itself as an independent prognostic factor. As immune checkpoint inhibitors recently changed the landmark of advanced G and GEJ adenocarcinomas treatment, we decided to perform a literature review to define the evidence-level of clinical data in older patients. This work underlined the lasting low -inclusion rate of older patients and -implementation rate of frailty screening tools in clinical trials in G/GEJ carcinomas. In the first-line metastatic setting, two prospective randomized phase III studies have specifically assessed the efficacy of chemotherapy in older patients with HER2-negative gastric cancers, demonstrating the feasibility of reduced dose oxaliplatin-based chemotherapy regimen in this population. Only few data are available in HER2-positive tumors, or in the second-line setting. Furthermore, no specific trial with immune checkpoint inhibitors was performed in older frail patients whereas their benefit/adverse events ratio make them attractive candidates in this patient's population. We conclude that older fit patients can be treated in the same way as younger ones and included in clinical trials. Improving the outcome of older frail patients should be the oncology community next focus by implementing targeted interventions before initiating cancer therapy and designing specific clinical trials. Frailty screening tools and geriatric data collection have to be implemented in routine-practice and clinical trials.

show abstract

“…These patients were defined as those with PS 2, weight loss 10-25% and/or aged ≥70 years. Although the median OS was 13.4 months, the rate of grade 3-5 toxicity was 76%, with 3 (7%) patients suffering a sudden death ( 80 ). Due to the high toxicity, this regime has not been adopted.…”

Section: Trial Evidence For Practicementioning

confidence: 99%

Real‑world challenge for clinicians treating advanced gastroesophageal adenocarcinoma (Review)

et al. 2021

View full text Add to dashboard Cite

Gastroesophageal adenocarcinoma (GOA) is a disease of older people. Incidence is rising in the developed world and the majority of patients present with advanced disease. Based on clinical trial data, systemic chemotherapy in the advanced setting is associated with improvements in quality of life and survival. However, there is a recognised mismatch between trial populations and the patients encountered in clinical practice in terms of age, comorbidity and fitness. Appropriate patient selection is essential to safely deliver effective treatment. In this narrative review, we discuss the challenges faced by clinicians when assessing real-world patients with advanced GOA for systemic therapy. We also highlight the importance of frailty screening and the current available evidence we can use to guide our management.

show abstract

Phase II trial of miniDOX (reduced dose docetaxel–oxaliplatin–capecitabine) in “suboptimal” patients with advanced gastric cancer (AGC). TTD 08-02

Abstract: Although miniDOX's toxicity (mainly PE)has been important, its activity has been promising in "suboptimal" pts with AGC, and this combination should be further investigated in this setting.

Cited by 14 publications

References 11 publications

Challenges in the treatment of gastric cancer in the older patient

Challenges in the treatment of gastric cancer in the older patient

Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature

Real‑world challenge for clinicians treating advanced gastroesophageal adenocarcinoma (Review)

Contact Info

Product

Resources

About